Among breast cancer tumors, triple negative breast cancer (TNBC) has poor prognosis, with an 11% 5-year survival rate due to the lack of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER-2) [1]. This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.